CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted
Drug / intervention
NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00283218
NCT00283218N/ACompleted
CompareCT.gov

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70. - A Randomised, Quadruple Cross-Over Trial

University of Aarhus·interventional·Posted Jan 27, 2006·Updated Aug 8, 2006

In Brief

A clinical study evaluating NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70 for Type 1 Diabetes. Completed, across 1 site.

Detailed Summary

The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin analogues will improve post prandial glycaemic control in patients with type 1 diabetes. OBJECTIVE: The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours following a standard test meal on four days respectively in subjects with type 1 diabetes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesDenmark
CollaboratorsNovo Nordisk A/S

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 27, 2006
Enrollment StartJan 1, 2006
Study CompletionAug 1, 2006
TodayJul 2, 2026
Posted 20.4 years ago

Interventions

NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70drug